We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Research Article

Comparison of scales to evaluate the progression of HIV-associated neurocognitive disorder

    Published Online:4 May 2010https://doi.org/10.2217/hiv.10.23

    Abstract

    Aim: First, to compare the characterization of neurocognitive deficits in milder stages of HIV-associated neurocognitive disorder (HAND) derived from existing dementia rating scales of the American Academy of Neurology (AAN) and Memorial Sloan Kettering (MSK) with the 2007 consensus (‘Frascati’) classification. Second, to identify potential sociodemographic and clinical predictors of HAND progression during 1-year follow-up. Methods: 104 HIV-infected subjects in an existing cohort system were evaluated with a medical history, exam, neuropsychological test battery and functional assessments. The degree of HAND was rated using the AAN, MSK and Frascati scales. The degree of concordance among these scales was determined. In addition, 45 subjects were reassessed for changes in their neurocognitive status at 1-year follow-up. Associations between age, education, sex, depression ratings, substance abuse, race, hepatitis C serostatus, CD4 count and progression of HAND were examined. Results: There was excellent concordance (γ > 0.8) among the Frascati, MSK and AAN ratings. Subjects rated as having minor cognitive motor disorder on the AAN scale (n = 45) were evenly split between Frascati rating of asymptomatic neurocognitive impairment (n = 24) and mild neurocognitive disorder (n = 21). At 1-year follow-up of 45 subjects, 31% had worsened, 13% had improved and 56% were stable. Predictors of progression included age older than 50 years (odds ratio: 5.57; p = 0.013) and female gender (odds ratio: 3.13; p = 0.036). Conclusion: The Frascati HAND rating scale has excellent concordance with previous neurocognitive rating scales and can be used to better characterize milder stages of cognitive impairment. Older individuals and women appeared to be more likely to show neurocognitive progression.

    Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

    Bibliography

    • 1  Price RW, Brew B: The AIDS dementia complex. J. Infect. Dis.158,1079–1083 (1988).
      Medline CASGoogle Scholar
    • 2  Janssen RS, Cornblath DR, Epstein LG: Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology41,778–785 (1991).▪ Describes in detail the American Academy of Neurology (AAN) rating scale.
      MedlineGoogle Scholar
    • 3  Antinori A, Arendt G, Becker JT et al.: Updated research nosology for HIV-associated neurocognitive disorders. Neurology69,1789–1799 (2007).▪▪ Describes in detail the Frascati rating scale.
      Medline CASGoogle Scholar
    • 4  Cardenas V, Meyerhoff D, Studholme C et al.: Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J. Neurovirol.15(4),324–333 (2009).
      Medline CASGoogle Scholar
    • 5  Gongvatana A, Schweinsburg BC, Taylor MJ et al.: White matter tract injury and cognitive impairment in human immunodeficiency virus-infected individuals. J. Neurovirol.15,187–195 (2009).
      MedlineGoogle Scholar
    • 6  Tozzi V, Balestra P, Bellagamba R et al.: Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J. Acquir. Immune Defic. Syndr.45,174–182 (2007).
      MedlineGoogle Scholar
    • 7  Childs EA, Lyles RH, Selnes OA et al.: Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology52,607–613 (1999).
      Medline CASGoogle Scholar
    • 8  Stern Y, McDermott MP, Albert S et al.: Factors associated with incident human immunodeficiency virus-dementia. Arch. Neurol.58(3),473–479 (2001).
      Medline CASGoogle Scholar
    • 9  McArthur JC, Hoover DR, Bacellar H et al.: for the Multicenter AIDS Cohort Study. Dementia in AIDS patients: incidence and risk factors. Neurology43,2245–2252 (1993).
      Medline CASGoogle Scholar
    • 10  McArthur JC, McDermott MP, McClernon D et al.: Attenuated CNS infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch. Neurol.61(11),1687–1696 (2004).
      MedlineGoogle Scholar
    • 11  Sacktor N, Skolasky R, Moxley M et al.: Magnetic resonance spectroscopy abnormalities and markers of oxidative stress for individuals with HIV-associated neurocognitive disorders. Neurology70,A4 (2008) (Abstract).
      Google Scholar
    • 12  Fahn S, Marsden C, Caine D: Recent developments in Parkinson’s disease. Macmillan Healthcare Information, Florham Park, NJ, USA (1987).
      Google Scholar
    • 13  Butters N, Grant I, Haxby J et al.: Assessment of AIDS-related cognitive changes: recommendations of the NIMH Workshop on Neuropsychological Assessment Approaches. J. Clin. Exp. Neuropsychol.12,963–978 (1990).
      Medline CASGoogle Scholar
    • 14  Goodman LA, Kruskal WH: Measures of association for cross classifications. J. American Statistical Association49,732–764 (1954).
      Google Scholar
    • 15  Hosmer DW, Lemeshow S: Applied Logistic Regression. Wiley, NY, USA (1989).
      Google Scholar
    • 16  Sacktor N: The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J. Neurovirol.8(Suppl. 2),115–121 (2002).
      Medline CASGoogle Scholar
    • 17  Bouwman FH, Skolasky RL, Hes D et al.: Variable progression of HIV-associated dementia. Neurology50,1814–1820 (1998).
      Medline CASGoogle Scholar
    • 18  Chiesi A, Vella S, Dally LG et al.; for AIDS in Europe Study Group: Epidemiology of AIDS dementia complex in Europe. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.11,39–44 (1996).
      Medline CASGoogle Scholar
    • 19  Cinque P, Vago L, Ceresa D et al.: Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS12,389–394 (1998).
      Medline CASGoogle Scholar
    • 20  Ellis RJ, Hsia K, Spector SA et al.: Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann. Neurol.42,679–688 (1997).
      Medline CASGoogle Scholar
    • 21  Brew BJ, Pemberton L, Cunningham P, Law MG: Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J. Infect. Dis.175,963–966 (1997).
      Medline CASGoogle Scholar
    • 22  McArthur JC, McClernon DR, Cronin MF et al.: Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann. Neurol.42,689–698 (1997).
      Medline CASGoogle Scholar
    • 23  Ellis RJ, Moore DJ, Childers ME et al.: Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch. Neurol.59,923–928 (2002).
      MedlineGoogle Scholar
    • 24  De Luca A, Ciancio BC, Larussa D et al.: Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology59,342–347 (2002).
      Medline CASGoogle Scholar
    • 25  McArthur JC: HIV dementia: an evolving disease. J. Neuroimmunol.157,3–11 (2004).▪▪ Review of HIV dementia in the pre-HAART and post-HAART eras.
      Medline CASGoogle Scholar
    • 26  Valcour V, Shiramizu B, Shikuma C et al.: Neurocognitive function among older compared with younger HIV-1 seropositive individuals, J. Neurovirol.8,69 (2002).
      MedlineGoogle Scholar
    • 27  Jevtovic DJ, Vanovac V, Veselinovic M, Salemovic D, Ranin J, Stefanova E: The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART. Biomed. Pharmacother.63(8),561–565 (2009).
      Medline CASGoogle Scholar
    • 28  Valcour VG, Shikuma CM, Watters MR, Sacktor NC: Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms. AIDS18(Suppl. 1),S79–S86 (2004).
      MedlineGoogle Scholar
    • 29  Valcour V, Watters MR, Williams AE, Sacktor N, McMurtray A, Shikuma C: Aging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapy. J. Neurovirol.14,362–367 (2008).
      Medline CASGoogle Scholar
    • 30  Liu X, Marder K, Stern Y et al.: Gender differences in HIV-related neurological progression in a cohort of injecting drug users followed for 3.5 years. J. NeuroAIDS1,17–29 (1996).
      Medline CASGoogle Scholar
    • 31  Velázquez I, Plaud M, Wojna V, Skolasky R, Laspiur JP, Meléndez LM: Antioxidant enzyme dysfunction in monocytes and CSF of Hispanic women with HIV-associated cognitive impairment. Neuroimmunology206(1–2),106–111 (2009).▪ Theories to explain female gender as a predictor of HIV-associated neurocognitive disorders (HAND) progression.
      Medline CASGoogle Scholar
    • 32  Mollace V, Nottet HS, Clayette P et al.: Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends Neurosci.24,411–416 (2001).▪ Theories to explain female gender as a predictor of HAND progression.
      Medline CASGoogle Scholar
    • 33  Stern Y: What is cognitive reserve? Theory and research application of the reserve concept. J. Int. Neuropsychol. Soc.8(3),448–460 (2002).
      MedlineGoogle Scholar
    • 101  Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, December 1, 1–161 (2009). www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
      Google Scholar